Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke


Phase 3 Results

Main Contacts

Name Phone E-mail
AstraZeneca NXY-059 Medical Science Director, MD Study Director

Other Locations

Name City State Country Status
Research Site Södertälje Sweden Unknown_status_icon
Research Site Glasgow United Kingdom Unknown_status_icon